BioCryst Stock Jumps After Pulling Out $200M Equity Raise

by Vandana Singh, Benzinga Editor

August 11, 2021 8:08 AM | 1 min read | Make a Comment

BioCryst Pharmaceuticals Inc BCRX has withdrawn its proposed public offering of $200 million of its stock and pre-funded warrants.
The Company says that it is well-capitalized, with cash, cash equivalents, restricted cash, and investments of $222.8 million as of June 30, 2021.
Based on expectations for revenue, operating expenses, and the option to access an additional $75 million from the existing credit facility, BCRX believes current cash runway into 2023.
Price Action: BCRX shares are up 8.45% at $16.49 during the premarket session on the last check Wednesday.

Posted In: Biotech Long Ideas News Health Care Financing Offerings Movers Trading Ideas General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.